Maunish Barvalia
Research Subjects
Research Interests
Maunish Barvalia has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Israel Matos
Department of Microbiology and Immunology, University of British Columbia, Life Sciences Institute , 2350 Health Sciences Mall, Vancouver, British Columbia , V6T 1Z3
16 shared publications - Kenneth W. Harder
Department of Microbiology and Immunology, University of British Columbia, Life Sciences Institute , 2350 Health Sciences Mall, Vancouver, British Columbia , V6T 1Z3
16 shared publications - Abhinandan Ranganathan
Department of Microbiology and Immunology, University of British Columbia, Life Sciences Institute, Vancouver, British Columbia, Canada
15 shared publications - Amy Short
ME Therapeutics Inc. Vancouver, British Columbia, Canada
15 shared publications - Andrew Gordon Robertson
Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency. Vancouver, British Columbia, Canada
15 shared publications - Brad H. Nelson
Deeley Research Centre, British Columbia Cancer - Victoria, University of British Columbia, Vancouver BC, Canada
15 shared publications
Latest Publications
- Open Access
- 22 July 2026
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 118 (8)
A DLL1-culture system to propagate murine patrolling monocytes from bone marrow progenitors
Patrolling monocytes (pMos) scavenge debris from vessel walls and mediate antibody-dependent cellular phagocytosis, making them attractive cell therapy candidates for cancer, atherosclerosis, and Alzheimer's disease. However, methods to generate pMos for cell therapy are not available. To address this, we developed a 2-step procedure to produce pMos in vitro from murine bone marrow (BM). First, myeloid progenitors were expanded and enriched from BM using cytokines for 4 d. Second, expanded progenitors were differentiated into pMos on delta-like ligand 1 (DLL1)-expressing monolayers for 8 d. We confirmed that in vitro grown pMos expressed the transcription factor Nr4a1 (Nur77) and other canonical pMos surface proteins, and depended on Notch signaling for their development. RNA-sequencing revealed that in vitro pMos expressed hallmark pMos genes, including Cx3cr1, Itgax (CD11c), CD43, Fcγr4, and Cd274 (PD-L1), and their gene signatures clustered closely with in vivo blood and BM pMos. Transcriptomic and phenotypic analyses further demonstrated that in vitro pMos were distinct from classical BM macrophages. Phagocytosis assays demonstrated the function of in vitro pMos in cancer cell uptake. Adoptive transfer studies demonstrated that in vitro pMos persisted within the circulation and lung vasculature during the early post-transfer period compared with BM-derived macrophages, consistent with the vascular-patrolling properties of pMos. Adoptive transfer of pMos reduced lung tumor burden in a metastatic model, supporting an anti-tumoral role for pMos and their ability to mediate immune surveillance in vivo. These findings demonstrate that the DLL1 culture system allows for propagation of functional pMos, enabling studies of pMos biology and their therapeutic potential.
- 22 July 2026
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 118 (8)
Open AccessA DLL1-culture system to propagate murine patrolling monocytes from bone marrow progenitors
Patrolling monocytes (pMos) scavenge debris from vessel walls and mediate antibody-dependent cellular phagocytosis, making them attractive cell therapy candidates for cancer, atherosclerosis, and Alzheimer's disease. However, methods to generate pMos for cell therapy are not available. To address this, we developed a 2-step procedure to produce pMos in vitro from murine bone marrow (BM). First, myeloid progenitors were expanded and enriched from BM using cytokines for 4 d. Second, expanded progenitors were differentiated into pMos on delta-like ligand 1 (DLL1)-expressing monolayers for 8 d. We confirmed that in vitro grown pMos expressed the transcription factor Nr4a1 (Nur77) and other canonical pMos surface proteins, and depended on Notch signaling for their development. RNA-sequencing revealed that in vitro pMos expressed hallmark pMos genes, including Cx3cr1, Itgax (CD11c), CD43, Fcγr4, and Cd274 (PD-L1), and their gene signatures clustered closely with in vivo blood and BM pMos. Transcriptomic and phenotypic analyses further demonstrated that in vitro pMos were distinct from classical BM macrophages. Phagocytosis assays demonstrated the function of in vitro pMos in cancer cell uptake. Adoptive transfer studies demonstrated that in vitro pMos persisted within the circulation and lung vasculature during the early post-transfer period compared with BM-derived macrophages, consistent with the vascular-patrolling properties of pMos. Adoptive transfer of pMos reduced lung tumor burden in a metastatic model, supporting an anti-tumoral role for pMos and their ability to mediate immune surveillance in vivo. These findings demonstrate that the DLL1 culture system allows for propagation of functional pMos, enabling studies of pMos biology and their therapeutic potential.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S2 compares the immune cell content in peripheral blood and spleens from immunocompetent, immunocompromised and G-CSFR-/- mice harboring MT or MTG-CSF-/- tumors.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S2 compares the immune cell content in peripheral blood and spleens from immunocompetent, immunocompromised and G-CSFR-/- mice harboring MT or MTG-CSF-/- tumors.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S4 shows that G-CSF and G-CSFR signaling inhibit DC development and activation, in DCs derived in a OP9-DLL1 co-culture system.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S4 shows that G-CSF and G-CSFR signaling inhibit DC development and activation, in DCs derived in a OP9-DLL1 co-culture system.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S4 shows that G-CSF and G-CSFR signaling inhibit DC development and activation, in DCs derived in a OP9-DLL1 co-culture system.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S4 shows that G-CSF and G-CSFR signaling inhibit DC development and activation, in DCs derived in a OP9-DLL1 co-culture system.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S1 shows the characterization of MT and MTG-CSF-/- cell lines and tumors, including surface protein expression, tumor volume/weight, and immune cell subset content. Composition of immune cells in blood and spleen of MT and MTG-CSF-/- mice is also shown.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S1 shows the characterization of MT and MTG-CSF-/- cell lines and tumors, including surface protein expression, tumor volume/weight, and immune cell subset content. Composition of immune cells in blood and spleen of MT and MTG-CSF-/- mice is also shown.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S1 shows the characterization of MT and MTG-CSF-/- cell lines and tumors, including surface protein expression, tumor volume/weight, and immune cell subset content. Composition of immune cells in blood and spleen of MT and MTG-CSF-/- mice is also shown.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S1 shows the characterization of MT and MTG-CSF-/- cell lines and tumors, including surface protein expression, tumor volume/weight, and immune cell subset content. Composition of immune cells in blood and spleen of MT and MTG-CSF-/- mice is also shown.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S3 shows deep phenotyping of Neut/MDSCs and B cells in the bone marrow of mice bearing MT or MTG-CSF-/- tumors, using FlowSOM applied in tSNE maps.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S3 shows deep phenotyping of Neut/MDSCs and B cells in the bone marrow of mice bearing MT or MTG-CSF-/- tumors, using FlowSOM applied in tSNE maps.